Advertisement
Screener

Veradermics, Inc (MANE) Operating Income

Veradermics, Inc Operating Income

Veradermics, Inc (MANE) reported Operating Income of -$29.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Income Statement

us-gaap:OperatingIncomeLoss · last filed 2026-08-11

  • Veradermics, Inc operating income (loss) for the quarter ending 2026-06-30 was -$29.55M.
  • Veradermics, Inc operating income (loss) for the quarter ending 2026-03-31 was -$29.86M.
  • Veradermics, Inc operating income (loss) for the quarter ending 2025-06-30 was -$16.07M.
  • Veradermics, Inc operating income (loss) for the quarter ending 2025-03-31 was -$12.91M.
  • Veradermics, Inc operating income (loss) for fiscal 2025 was -$72.35M.
  • Veradermics, Inc operating income (loss) for fiscal 2024 was -$26.78M.
Period endOperating Income (Loss) 3 monthOperating Income (Loss) 6 monthOperating Income (Loss) 12 month
2026-06-30-$29.55M
10-Q · filed 2026-08-11
-$59.41M
10-Q · filed 2026-08-11
2026-03-31-$29.86M
10-Q · filed 2026-05-12
2025-12-31-$72.35M
10-K · filed 2026-03-30
2025-06-30-$16.07M
10-Q · filed 2026-08-11
-$28.99M
10-Q · filed 2026-08-11
2025-03-31-$12.91M
10-Q · filed 2026-05-12
2024-12-31-$26.78M
10-K · filed 2026-03-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Erasca, Inc. (ERAS)United States$5.073B-19.96
Dianthus Therapeutics, Inc. /DE/ (DNTH)United States$5.082B-27.79
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07
Edgewise Therapeutics, Inc. (EWTX)United States$4.470B-22.23
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
Viking Therapeutics, Inc. (VKTX)United States$4.287B-8.51
Indivior Pharmaceuticals, Inc. (INDV)$4.250B14.09
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
Tango Therapeutics, Inc. (TNGX)United States$4.154B-42.53
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76